Pan-cancer Genetic Testing Market Report – Research, Industry Analysis Reports and Market Demands

Global Pan-cancer Genetic Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Pan-cancer Genetic Testing Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Pan-cancer Genetic Testing by Company Revenue
- 3.2.2 Top 3 Pan-cancer Genetic Testing Players Market Share in 2025
- 3.2.3 Top 6 Pan-cancer Genetic Testing Players Market Share in 2025
3.3 Pan-cancer Genetic Testing Market: Overall Company Footprint Analysis
- 3.3.1 Pan-cancer Genetic Testing Market: Region Footprint
- 3.3.2 Pan-cancer Genetic Testing Market: Company Product Type Footprint
- 3.3.3 Pan-cancer Genetic Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Pan-cancer Genetic Testing Consumption Value and Market Share by Type (2021-2026)
4.2 Global Pan-cancer Genetic Testing Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Pan-cancer Genetic Testing Consumption Value Market Share by Application (2021-2026)
5.2 Global Pan-cancer Genetic Testing Market Forecast by Application (2027-2032)

6 North America

6.1 North America Pan-cancer Genetic Testing Consumption Value by Type (2021-2032)
6.2 North America Pan-cancer Genetic Testing Market Size by Application (2021-2032)
6.3 North America Pan-cancer Genetic Testing Market Size by Country
- 6.3.1 North America Pan-cancer Genetic Testing Consumption Value by Country (2021-2032)
- 6.3.2 United States Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 6.3.3 Canada Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Pan-cancer Genetic Testing Consumption Value by Type (2021-2032)
7.2 Europe Pan-cancer Genetic Testing Consumption Value by Application (2021-2032)
7.3 Europe Pan-cancer Genetic Testing Market Size by Country
- 7.3.1 Europe Pan-cancer Genetic Testing Consumption Value by Country (2021-2032)
- 7.3.2 Germany Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 7.3.3 France Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 7.3.5 Russia Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 7.3.6 Italy Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Pan-cancer Genetic Testing Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Pan-cancer Genetic Testing Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Pan-cancer Genetic Testing Market Size by Region
- 8.3.1 Asia-Pacific Pan-cancer Genetic Testing Consumption Value by Region (2021-2032)
- 8.3.2 China Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 8.3.3 Japan Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 8.3.5 India Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 8.3.7 Australia Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)

9 South America

9.1 South America Pan-cancer Genetic Testing Consumption Value by Type (2021-2032)
9.2 South America Pan-cancer Genetic Testing Consumption Value by Application (2021-2032)
9.3 South America Pan-cancer Genetic Testing Market Size by Country
- 9.3.1 South America Pan-cancer Genetic Testing Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Pan-cancer Genetic Testing Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Pan-cancer Genetic Testing Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Pan-cancer Genetic Testing Market Size by Country
- 10.3.1 Middle East & Africa Pan-cancer Genetic Testing Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)
- 10.3.4 UAE Pan-cancer Genetic Testing Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Pan-cancer Genetic Testing Market Drivers
11.2 Pan-cancer Genetic Testing Market Restraints
11.3 Pan-cancer Genetic Testing Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Pan-cancer Genetic Testing Industry Chain
12.2 Pan-cancer Genetic Testing Upstream Analysis
12.3 Pan-cancer Genetic Testing Midstream Analysis
12.4 Pan-cancer Genetic Testing Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Pan-cancer Genetic Testing market size was valued at US$ 6462 million in 2025 and is forecast to a readjusted size of US$ 15343 million by 2032 with a CAGR of 13.1% during review period.
Pan-cancer Genetic Testing refers to clinical diagnostic and precision oncology solutions that use targeted next-generation sequencing, whole-exome sequencing, whole-transcriptome sequencing, or multimodal molecular analysis to profile cancer-related genomic alterations and biomarkers across multiple solid tumors or hematologic malignancies. Major targets include single nucleotide variants, insertions and deletions, copy number alterations, gene fusions and rearrangements, as well as genomic signatures such as tumor mutational burden, microsatellite instability, and homologous recombination deficiency. Commercial offerings include centralized laboratory testing services, tissue and liquid biopsy assay kits, integrated testing systems, and associated bioinformatics solutions. These tests are mainly used for targeted therapy selection, immunotherapy assessment, clinical trial matching, molecular classification, and resistance analysis. Key upstream inputs include specimen collection components, nucleic acid extraction and library preparation reagents, capture probes, sequencing flow cells, quality controls, sequencing platforms, bioinformatics algorithms, and genomic databases. Major downstream customers include hospitals, cancer centers, independent clinical laboratories, pathology laboratories, pharmaceutical and biotechnology companies, and clinical research organizations. The estimated industry gross margin is generally approximately 50%–70%.
The global Pan-cancer Genetic Testing market is shifting from sequential single-gene and tumor-specific testing toward comprehensive genomic profiling. As the number of actionable alterations, immunotherapy biomarkers, and tumor-agnostic treatment indications increases, sequential testing has become less efficient because of tissue consumption, longer turnaround times, and cumulative cost. Large genomic panels can evaluate multiple variant classes and genomic signatures in a single test and are therefore gaining adoption among patients with advanced solid tumors or limited standard treatment options. North America is primarily characterized by centralized reference laboratory services, while Europe and Japan rely more heavily on combinations of approved products and designated hospital networks. China has developed a mixed structure that includes centralized testing services, hospital-based laboratories, and locally manufactured standardized assay kits.
Tissue-based testing remains the foundation of comprehensive genomic profiling, but liquid biopsy is becoming an important complementary option for patients with insufficient tissue, high biopsy risk, or a need for faster results. Testing scope is expanding from targeted panels containing several hundred genes toward integrated DNA and RNA analysis, matched tumor-normal sequencing, whole-exome sequencing, and whole-transcriptome sequencing. RNA analysis can improve the detection of gene fusions and abnormal splicing events, while matched-normal analysis can distinguish somatic alterations from germline variants and clonal hematopoiesis signals. Future differentiation will depend increasingly on analytical performance in low-tumor-content samples, fusion detection, turnaround time, the strength of clinical evidence, and the actionability of report interpretation rather than on gene count alone.
Market growth is supported by the expansion of precision oncology, increasing numbers of tumor-agnostic targeted and immunotherapy indications, stronger guideline recommendations, and broader availability of hospital NGS infrastructure. Drug development programs increasingly stratify patients according to shared molecular alterations across different tumor types rather than according to the organ of origin alone. Pharmaceutical demand for companion diagnostic development, clinical trial recruitment, biomarker strategy, and real-world evidence also provides testing companies with revenue opportunities beyond routine patient testing. As sequencing costs decline, workflows become more automated, and reimbursement coverage improves, pan-cancer testing is expected to extend from late-stage and rare cases toward earlier treatment stages and a broader patient population.
The industry nevertheless faces constraints related to specimen quality, testing cost, reimbursement, and the clinical conversion of genomic findings. Differences in gene coverage, sequencing depth, variant thresholds, and reporting rules may lead to inconsistent results across laboratories. Some patients have potentially actionable alterations but cannot access the matched treatment because of regulatory indications, drug availability, or the location of relevant clinical trials. Competition between hospital-developed assays and centralized laboratory services may place pressure on pricing and lead to duplicated infrastructure investment. Future competitive advantage will depend on regulatory approvals, companion diagnostic partnerships, liquid biopsy performance, interpretation capabilities, reimbursement access, and evidence of clinical utility, while companies must also address incidental germline findings, informed consent, and the security of genomic data.
This report is a detailed and comprehensive analysis for global Pan-cancer Genetic Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pan-cancer Genetic Testing market size and forecasts, in consumption value ($ Million), 2021-2032
Global Pan-cancer Genetic Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Pan-cancer Genetic Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Pan-cancer Genetic Testing market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pan-cancer Genetic Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pan-cancer Genetic Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Guardant Health, Caris Life Sciences, Tempus AI, Labcorp, NeoGenomics, Exact Sciences, Personalis, Illumina, Thermo Fisher Scientific, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Pan-cancer Genetic Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Tissue-based Testing
Liquid Biopsy Testing
Other
Market segment by Testing Scope
Medium Panels (50–199 Genes)
Large Panels (200–599 Genes)
Extended Panels (600–999 Genes)
Other
Market segment by Technology
Targeted NGS
Whole-exome Sequencing
Whole-transcriptome Sequencing
Other
Market segment by Application
Hospitals and Cancer Centers
Independent Clinical Laboratories
Other
Market segment by players, this report covers
Roche
Guardant Health
Caris Life Sciences
Tempus AI
Labcorp
NeoGenomics
Exact Sciences
Personalis
Illumina
Thermo Fisher Scientific
QIAGEN
Agilent Technologies
SOPHiA GENETICS
Sysmex
Burning Rock Biotech
Genetron Health
Geneseeq
BGI Genomics
Amoy Diagnostics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pan-cancer Genetic Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pan-cancer Genetic Testing, with revenue, gross margin, and global market share of Pan-cancer Genetic Testing from 2021 to 2026.
Chapter 3, the Pan-cancer Genetic Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Pan-cancer Genetic Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pan-cancer Genetic Testing.
Chapter 13, to describe Pan-cancer Genetic Testing research findings and conclusion.

Buy now